Last reviewed · How we verify
Co-Latanoprost
Co-Latanoprost is a fixed-dose combination of latanoprost (a prostaglandin F analog) and another agent that works synergistically to reduce intraocular pressure in glaucoma.
Co-Latanoprost is a fixed-dose combination of latanoprost (a prostaglandin F analog) and another agent that works synergistically to reduce intraocular pressure in glaucoma. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Co-Latanoprost |
|---|---|
| Also known as | 02254786 |
| Sponsor | Dr. David Yan |
| Drug class | Prostaglandin analog combination |
| Target | FP receptor (prostaglandin F receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. The combination formulation enhances efficacy through complementary mechanisms to achieve greater IOP reduction than monotherapy alone.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-Latanoprost CI brief — competitive landscape report
- Co-Latanoprost updates RSS · CI watch RSS
- Dr. David Yan portfolio CI